Waters Accelerates Quantitative Mass Spectrometry With New Application on waters_connect Informatics Platform
12.1.2022 17:10:00 EET | Business Wire | Press release
Waters Corporation (NYSE:WAT) today announced it is expanding its waters_connect™ informatics software platform to support customers analyzing food and environmental samples with Waters’ tandem quadrupole mass spectrometers. The new MS Quan™ application for waters_connect allows laboratories screening large numbers of samples, or those who may be quantifying hundreds of small molecule components and contaminants in a single run, a more efficient means of processing and reviewing data and identifying batch-to-batch variations.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220112005625/en/
For laboratories using Waters™ Xevo™ mass spectrometers, the MS Quan app quickly and accurately converts measurement data on compounds into meaningful results in a traceable, compliant, and secure manner. Featuring a web-based user interface, the MS Quan app includes an Exception Focused Review (XFR) feature that can help cut data review time by up to 50% by allowing users to focus on only those results that fall outside the user-determined ruleset.
“The waters_connect platform provides a backbone for the connected lab of the future where data is no longer siloed but can be securely shared among a community of connected scientists using apps that talk to each other,” said Jon Pratt, Senior Vice President, Waters Corporation. “MS Quan is a great example of the new applications and quality improvements we are bringing to our customers via waters_connect and its platform architecture designed for data integrity, compliance, security and accessibility.”
Several scientists from Primoris (Zwijnaarde, Belgium), a global contract laboratory, participated in the beta testing of the MS Quan software application. Primoris measures pesticide residues and contaminants in food and animal feed as well as analyzing food additives, supplements, and essential oils.
“We’ve used MassLynx and TargetLynx from Waters for a very long time so we knew from the beginning the potential that this new app will offer," said Janne Dombrecht, Analysis Lead, Primoris Belgium. “The final product is exactly what we were looking for. Our close relationship with Waters and being able to test this product to make sure it is optimal for our methods has been a win-win situation. We’re excited to roll it out across Primoris!”
The waters_connect for quantitation workflow and MS Quan app are now available worldwide as an upgrade for select Waters’ tandem quadrupole mass spectrometers.i
Additional Resources
- Learn more about the MS Quan app on waters_connect
- Read the blog: “Helping Laboratories Embrace New Era of Efficiency”
- Download the white paper: “The Benefits of waters_connect MRM Processing Application, MS Quan”
About Waters Corporation (www.waters.com)
Waters Corporation (NYSE:WAT), a global leader in analytical instruments and software, has pioneered chromatography, mass spectrometry, and thermal analysis innovations serving the life, materials, and food sciences for more than 60 years. With more than 7,400 employees worldwide, Waters operates directly in 35 countries, including 14 manufacturing facilities, and with products available in more than 100 countries.
Waters, MS Quan, Xevo, MassLynx, TargetLynx, and waters_connect are trademarks of Waters Corporation. Primoris is a trademark of Primoris Belgium.
____________________________
i At this time the MS Quan app is for small molecule quantification studies and compatible with Waters Xevo TQ-XS, a Waters Xevo TQ-S micro and Waters TQ-S cronos tandem quadrupole mass spectrometers with either an ACQUITY I-Class, H-Class System or ACQUITY Premier System front-end. Additionally, waters_connect software is currently available as an “on-premise” only workstation product.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220112005625/en/
Contact information
Brian J. Murphy
PR Manager, Corporate Communications
Waters Corporation
brian_j_murphy@waters.com
+1 508-482-2614
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
KATE Launches "KABUKE: Break Convention" Kabuki-Inspired International Campaign17.7.2026 10:00:00 EEST | Press release
Global cosmetics brand KATE launched “KABUKE: Break Convention,” a new international campaign drawing on elements of Kabuki, the traditional Japanese performing art. The campaign debuted on Wednesday, July 8, 2026. In this campaign, KATE’s shadow enhancing makeup—rooted in Japanese aesthetics—was paired with the Kabuki spirit inherited from traditional Kabuki theater to communicate the value of individuality and self‑expression through makeup on a global scale. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260708829427/en/ KATE international campaign “KABUKE: Break Convention” key visual. Dedicated website: https://www.kate-global.net/my/special/kate_kabuki/ Since its founding, KATE has championed the slogan “NO MORE RULES.,” offering makeup that defies convention and empowers individuals to express their identity and bring out confidence. At the heart of this vision is the brand’s signature shadow enhancing makeup approach
Yoshihiro Shimamura Joins the Marché du Film’s “Investors Circle 2026” as an Invited Investor, Backing a New Feature Film17.7.2026 04:00:00 EEST | Press release
Shimamura Yoshihiro Film Production Co., Ltd. (Head office: Osaka, Japan; Representative Director: Yoshihiro Shimamura), a company active in film production and investment, today announced that Representative Director Yoshihiro Shimamura has decided to invest in an international feature film after being invited to the “Investors Circle 2026” — a distinction that reflects his standing as one of the field’s most highly regarded producers and investors. Hosted by the Marché du Film, the business arm of the Festival de Cannes and one of the world’s largest film markets, the Investors Circle is an invitation-only summit that connects a select group of private investors with high-end feature films during early-stage financing. Held in Cannes, France, May 16-17, 2026, it brings internationally acclaimed directors and producers together with investors around a curated slate of projects in development. During the summit, Shimamura attended private pitching sessions and, after individual meeting
Meiji Seika Pharma: Results from the Global Phase III Trial (Integral-2) of Nacubactam, a Novel β-Lactamase Inhibitor, Highlighted in The Lancet Microbe ’s Coverage of ESCMID Global Congress 202617.7.2026 04:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, President and Representative Director: Toshiaki Nagasato) today announced that results from the global Phase III trial (Integral-2) of nacubactam (Development Code: OP0595), a novel β-lactamase inhibitor, were highlighted in The Lancet Microbe’s coverage of ESCMID Global Congress 2026 (held in Munich, Germany). As highlighted in The Lancet Microbe’s coverage, the key findings presented by Meiji Seika Pharma at ESCMID Global Congress 2026 are as follows: The Integral-2 study (jRCT2031230076) is a global Phase III clinical trial that enrolled patients with complicated urinary tract infections, acute uncomplicated pyelonephritis, hospital-acquired bacterial pneumonia, ventilator-associated bacterial pneumonia, or complicated intra-abdominal infections caused by carbapenem-resistant Gram-negative bacteria (excluding Acinetobacter species). The study has achieved the prespecified study objectives. For the primary endpoint of overall treatme
Takeda’s Zasocitinib Demonstrates Consistent, High Rates of Skin Clearance Across the Body, Including Hard-to-Treat and High-Impact Sites, in Phase 3 Psoriasis Studies17.7.2026 01:00:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK) announced new data from the two pivotal Phase 3 studies of zasocitinib (TAK-279), a next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented at the 2026 American Academy of Dermatology (AAD) Innovation Academy, these secondary endpoint data show that zasocitinib demonstrated consistent and high rates of skin clearance across hard-to-treat, high-impact sites, including the scalp, nails, palms and soles, compared with placebo.1-5 These data build on the topline results from the Phase 3 randomized, multicenter, double-blind, placebo- and active comparator-controlled LATITUDE PsO 3001 and 3002 studies.2,6 In those studies, about 70% of patients treated with zasocitinib achieved static Physician Global Assessment (sPGA) 0/1 (clear or almost clear skin) at week 16, with a significantly greater Psoriasis Area and Severity Index (PASI) 75 response rate seen as early as w
Merz Completes Inaugural €450 Million Schuldschein Loan Issuance17.7.2026 00:36:00 EEST | Press release
The Merz Group has successfully completed its first-ever Schuldschein loan issuance, placing a total volume of €450 million in the debt capital market – a multiple of three relating to the launch volume. The debut transaction was significantly oversubscribed and attracted strong interest from all investor groups. The proceeds were settled and paid out today. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260716926041/en/ Dr. Almuth Steinkühler, Chief Financial Officer Merz Group The transaction comprises both fixed- and floating-rate tranches with maturities of three, five, seven, and ten years. Around 50 German and international investors participated, representing a broad range of institutions, including private banks, German federal state-owned banks, public savings banks, cooperative banks, pension funds and occupational pension institutions. With the successful placement, Merz has further diversified its funding base by
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom